Suvizumab
Based on 1 Customer Validation
Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : ≥99.0%
- CAS 番号: 914257-21-9
- 分子量:146.38 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Virus
|
HIV-1 |
HIV-189.6 0.2 μg/mL (IC50) |
HIV-1MN 0.1 μg/mL (IC50) |
HIV-1SF2 1.0 μg/mL (IC50) |
体外実験
Suvizumab shows highly resistant to pseudotyped virus with the G314E mutation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
Suvizumab (45 mg/kg; i.v.; once a week for 2 months) reduces the loss of CD4 T cells in lymphoid tissue in male cynomolgus monkeys infected with simian/human immunodeficiency virus-C2/1[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Envelope glycoprotein gp120 Protein, HIV-1 can bind Suvizumab. The EC50 for this effect is 9.057 ng/mL.
化学情報
-
CAS 番号 914257-21-9
-
性状 Liquid
-
分子量 146.38 kDa
-
Color Colorless to light yellow
-
SMILES
[Suvizumab]
-
別名
KD-247
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Matsushita S, et al. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS. 2015 Feb 20;29(4):453-62. [Content Brief]
[2]. Eda Y, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J Virol. 2006 Jun;80(11):5563-70. [Content Brief]
[3]. Yoshimura K, et al. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS. 2006 Oct 24;20(16):2065-73. [Content Brief]
[4]. Murakami T, et al. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue. AIDS. 2009 Jul 31;23(12):1485-94. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Suvizumab 関連分類
HY-P99584 関連分類
Powered by Bioz